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Tuberculosis (TB) is the leading cause of mortality as a single infectious agent globally with
increasing numbers of case notification in developing countries. This study seeks to investigate the clinical and socio-demographic factors of time to TB treatment interruption among
Tuberculosis patients in Kiambu County, 2016–2019. We retrospectively analyzed data for
all treatment outcomes patients obtained from TB tracing form linked with the Tuberculosis
Information Basic Unit (TIBU) of patients in Kiambu County health facilities using time to
treatment interruption as the main outcome. Categorical variables were presented using frequency and percentages. Kaplan-Meir curve was used to analyze probabilities of time to
treatment interruptions between intensive and continuation phases. Log-rank test statistics
was used to compare the equality of the curves. Cox proportion model was used to determine determinants of treatment interruption. A total of 292 participants were included in this
study. Males were 68%, with majority (35%) of the participants were aged 24–35 years;
5.8% were aged 0–14 years and 5.1% aged above 55 years. The overall treatment success
rate was 66.8% (cured, 34.6%; completed 32.2%), 60.3% were on intensive phase of treatment. Lack of knowledge and relocation were the major reasons of treatment interruptions.
Patients on intensive phase were 1.58 times likely to interrupt treatment compared to those
on continuation phase (aHR: 1.581; 95%CI: 1.232–2.031). There is need to develop TB
interventions that target men and middle aged population in order to reduce treatment interruption and increase the treatment success rates in the County and Country.

Introduction
Tuberculosis (TB) remains a major public health concern globally. Though an ancient disease,
it is still among the top ten causes of mortality globally from a single infectious agent [1]. In
2018, the estimated number of TB cases were10 million [1] worldwide with 1.2 million estimated among the Human Immunodeficiency Virus (HIV) negative patients and 251,000
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among TB-HIV co-infected patients [1]. The number of TB cases notified worldwide in 2018
were notably higher among the male gender at 56% [1].
Kenya, a low middle income country is among 30 high burden countries for TB and among
14 countries that suffer a triple burden of TB, TB-HIV and Multi-drug resistant (MDR) TB clients [1–3]. In 2018 alone, the country reported 96,478 TB cases; a 13.2% increment from the
previous year. In the same year, TB-HIV co-infection notified cases contributed 26.6% [4].
The country has come a long way in enhancing TB diagnosis through equitable distribution of
diagnostic tools like expanded use of x-ray, availability of gene-xpert machines as well as provision of microscopy for both diagnosis and follow-up for TB patients. Further, initiatives are
still in place in bridging the gap of 40% missing TB cases reported by the TB prevalence survey
of 2015-2016 [5]. Some of the initiatives include health facility active case finding, contact tracing by Community Health Volunteers (CHVs), public private partnerships as well as Kenya
Innovation Challenge for TB. All these are aimed at finding missing people with TB in the
communities and linking them to TB diagnosis and treatment clinics through innovative
strategies.
The strategic development goal (SDG) number three aims to improve good health and
well-being among all people with one of the targets being to end TB and HIV epidemics globally by 2030 [1]. Similarly, the End TB strategy aims at reducing the number of deaths due
to TB by 90% as well as reduce the TB incidence by 80% by 2030 [4]. Likewise, the Kenya
National TB programme aims at ensuringthat all the TB notified patients adhere to the recommended regimen and successfully complete treatment. These milestones will not be realized if
the challenges facing treatment interrupters are not adequately addressed.
In a bid to strengthen retention to care among the TB patients, Kiambu County, with the
support from Respiratory Society of Kenya (RESOK) through Amref Health Africa, has
engaged community health volunteers (CHVs) across the health facilities offering diagnostic
and/or treatment services to TB patients. With support from the health care workers (HCWs),
CHVs actively follow up patients who either have missed an appointment or interrupted treatment for more than 2 weeks. The treatment interrupters are documented in the Ministry of
Health (MOH) community reporting tool- treatment interruption tracing form.
To further improve the adherence, the National TB programme in Kenya adopted the
Direct Observation Therapy (DOT) for TB patients as recommended by the World Health
Organization (WHO) in 1993 [6] where all patients with TB disease are supervised while taking their medication. However, there are patients that fail to keep their appointment dates
hence missing their treatment. The interruption to treatment could range from weeks to
months. During this time, the patients risk transmitting TB disease to their close contacts,
could develop resistance due to drug interruption or end up with unfavorable outcomes such
as death.
Kiambu county in 2018, had a notable 5.9% of patients interrupting their treatment either
during intensive phase or continuation phase, a percentage that is above the national level of
5.4% [7]. A study conducted in Meru Kenya, found that more males interrupted treatment
and cited forgetfulness as the commonest reason for treatment interruption [8]. In addition, a
study conducted in Zambia revealed the commonest reasons for treatment interruption being
feeling better, low level of knowledge on treatment completion benefits and drug side effects.
Other contributory factors found among treatment interrupters in Uganda was change of the
treatment facility for the patient [9]. Social factors found were lack of formal employment, lack
of family support as well as smear positivity at time of diagnosis [10]. Other factors identified
in a study conducted in South Sudan were long distance to the health facility, stigma from the
society, high cost of transportation, traditional beliefs as well as rural residency [11]. In NorthWest Ethiopia, a cross-sectional study conducted revealed that patients with more than one
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co-morbidity, poor patient-provider relationship and low knowledge on TB contributed significantly to treatment interruption [12]. A systematic study review on qualitative research
conducted on patient adherence to tuberculosis treatment identified areas that included financial burden, law and immigration, knowledge, attitude, beliefs, family, community and household support [13] as being key factors to treatment interruption.
There is paucity of data on treatment interruption and outcomes in Kiambu County. The
study will bridge the information gap by investigating the socio-demographic and determinants of time to interruption and treatment outcomes between 2016 and 2019. This information will be vital in strengthening the health system in the County and every effort put to
ensure the barriers highlighted are addressed to improve the treatment success among the TB
patients even as the government strives to reduce the number of new TB infections by 90% by
2030.

Methods
Data collection
The data for this study were extracted from the MOH Tuberculosis treatment interruption
tracing form attached as additional file (S1 File) for the period 2016 to 2019 which captured
the following variables: age, sex, location of health facility treatment site and type of TB that
the participant is suffering from, date of treatment initiation, date of treatment interruption
and tracing outcomes.
The data in the MOH TB tracing form is collected by trained CHVs as they follow up
patients who interrupt treatment. The patients who are traced by the CHVs are referred back
to the health facility and linked to the Community Health Extension Worker (CHEW) for continuation of care and treatment. The information captured in the tracing form is submitted to
Respiratory Society of Kenya (RESOK) for entry into the Grants Management Information
System (GMIS) by the data clerks and data manager based at Amref Health Africa. The data
entered is verified against the physical form to ensure accuracy in entry. The treatment outcome data was obtained by linking the data from GMIS and Tuberculosis Information Basic
Unit (TIBU) system.

Study design
This was a retrospective study of TB patients in Kiambu County health facilities who interrupted treatment, traced and successfully referred back to treatment. The study period was
from 1stJanuary 2016 to 31stDecember 2019.

Study site and participants
Kiambu County, one of the 47 Counties in Kenya, has a population of 2.4 million people and
is ranked among the top ten TB high burden counties in the country. It is divided into 12
administrative sub-counties with a total of 505 health facilities. Of these, 108 (21%) are public
health facilities, 64 (13%) are faith based organizations and 333 (66%) are private facilities.
Among the public health facilities, there are 70 level two, 24 level three, 11 level 4 and three
level 5 health facilities [14]. Level 2 and 3 health facilities offer basic medical services while
level 4 and 5 facilities offer tertiary health services. The study was conducted in level 3, 4 and 5
health facilities in Kiambu County. Of all the health facilities in Kiambu County, there are 142
treatment sites for TB, 82 diagnostic sites and 7 gene-Xpert machines for diagnosis purposes.
The study population included all TB patients who interrupted treatment but were returned
to care and treatment both from the public and private health sector across the12 sub-counties
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of Kiambu County. There was no formal sample size calculation as this was a retrospective
study, however the final sample included in the study was assumed to have enough power to
detect a difference between the outcome and explanatory variables. We excluded all TB
patients who did not interrupt treatment, already active in care and those who could not be
traced back into the treatment.

Sampling procedure
All the patients interrupting treatment in the period of 2016to 2019 and were successfully
traced formed the study sample.
Study variables. The dependent variable for this study was time to treatment interruption
measured as time from TB treatment initiation to the time the participant interrupted treatment. The independent variables included sex of the respondents (male and female), age at the
time of data collection measured on a continuous scale, BMI categorized into obese, normal,
moderate, overweight and severe; HIV status measured on binary scale as positive and negative; type of TB (PTB and EPTB) and TB treatment phase (continuation and intensive). All
variables were considered important in explaining the outcome of interest and were therefore
adjusted for in the Cox proportion model.

Statistical analysis
All the data extracted from GMIS and TIBU were exported into an excel database. Categorical
data were expressed as frequency and percentage. Kaplan-Meir curve was used to analyze the
probability of time to treatment interruption for patients on intensive and continuation phase
of treatment. The equality of the curves was compared using Log-Rank, Breslow or TaroneWare test statistics. Cox proportion hazards model was performed to determine socio-demographic and clinical factors associated with the time to treatment interruption both for
Univariate and multivariate models. All statistical Analysis was conducted using STATA version 15 (Stata Corporation, College Station, Texas, USA) and all tests were two-tailed with pvalues < 0.05 considered statistically significant.

Ethical considerations
The study was approved by the Amref health Africa in Kenya scientific and ethical review
committee by providing a waiver of consent because this was a retrospective study of routinely
collected data; application approval P796/2020. Strict confidentiality was ensured throughout
the study period and final analysis dataset de-identified prior to analysis. The study was conducted in accordance with the Declaration of Helsinki.

Results
General characteristics
We included 292 participants who interrupted TB treatment in Kiambu County health facilities in the period of 1st January 2016- 31st December 2019. Males were 200(68%) while female
were 92 (32%). Majority (35%) of the study participants were aged 25–34 years, followed by
those aged between 35–44 years (26%). The age groups 0–14 years and above 55 year constituted 5.8% and 5.1% respectively. Most of the participants were from Kiambaa (23%), Githunguri (21%) and Thika (20%) sub-counties. Among the study participants, Pulmonary TB was
the most common type of TB (98.6%, n = 288) and the rest (n = 4) had extra pulmonary TB.
Of the participants with Pulmonary TB, 265(92.0%) showed positive smear results while the
rest (n = 3) showed smear negative. Majority (43%) of the patients had normal BMI, followed
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by those with moderate BMI (30.8%), 16.8% had severe BMI, and the rest (9%) were either
obese or overweight. The proportion of TB-HIV co-infection was estimated to be 29% (n = 85)
while 60.3% (n = 176) of the participants were in intensive phase of the treatment as shown in
Tables 1 and 2.

Outcomes of treatment
Fig 1 shows the treatment outcomes of the patients. The overall treatment success rate (TSR)
was 66.8% (either cured (34.6%) or completed (32.2%), 20.9% were lost to follow-up, 5.8%
transfer out, 4.1% died, not completed treatment, non-TB was each 1%, and 0.3% were treatment failures.

Reasons for treatment interruption
The most common reason for the treatment interruptions were lack of knowledge (17.8%)
folowed by relocation (17.1%), travelled (12.0%) felt better(11.0%), and other reasons are summarized in Fig 2. Others inlcudes: financial contraints, drug resistant cases, scared, long distance each at 0.3%, worsening condition, and pill burden each at 0.7%.

Kaplan Meir survival curves for treatment interruptions
Fig 3 shows the Kaplan-Meir curves for the cumulative risk of treatment interruptions between
intensive and continuation phase of the treatment. The interruption probability at the
Table 1. Socio-demographic characteristics of TB patients attending public hospitals in Kiambu County, 2015–
2019 (N = 292).
Variable

Frequency

Percent

Sex
Male

200

68.5

Female

92

31.5

0–4

8

2.7

5–9

4

1.4

10–14

5

1.7

15–24

49

16.8

Age-group in years

25–34

101

34.6

35–44

75

25.7

45–54

35

12

55–64

8

2.7

65+

7

2.4

Sub-county of residence
Gatundu

25

8.6

Githunguri

60

20.6

Juja

18

6.2

Kabete

15

5.1

Kiambaa

66

22.6

Kiambu

5

1.7

Kikuyu

9

3.1

Lari

15

5.1

Limuru

12

4.1

Ruiru

10

3.4

Thika

57

19.5

https://doi.org/10.1371/journal.pone.0248820.t001
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Table 2. Clinical characteristics of TB patients attending public hospitals in Kiambu County, 2015–2019
(N = 292).
Variable

Frequency

Percent

PTB

288

98.6

EPTB

4

1.4

Smear+

265

92.0

Smear-

23

8.0

Normal

126

43.2

Moderate

90

30.8

Obese

17

5.8

Overweight

10

3.4

Severe

49

16.8

Negative

207

70.9

Positive

85

29.1

Intensive

176

60.3

Continuation

116

39.7

Type of TB

Initial smear(n = 288)

BMI

HIV status

Phase

https://doi.org/10.1371/journal.pone.0248820.t002

Fig 1. TB treatment outcomes.
https://doi.org/10.1371/journal.pone.0248820.g001
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Fig 2. Reasons for missed visits.
https://doi.org/10.1371/journal.pone.0248820.g002

intensive phase was higher than of those in the continuation phase. As time increases the two
probabilities were the same. The log rank test showed that there was a significant difference
between the two curves as shown by the different tests.
The results of Cox regression survival model are summarized in Table 3; only phase of treatment was significantly associated with the time to treatment interruption. Patients on intensive
phase of treatment were 1.58 times more likely to interrupt treatment compared to those on
continuation phase (aHR: 1.581; 95%CI: 1.232–2.031). Sex, type of TB, BMI, and HIV status
were not statistically significant.

Discussion
Treatment interruption in Kiambu County was shown to be prevalent during the intensive
phase compared to continuation phase. This could be due to insufficient health education
given to the participants upon being diagnosed with TB. These results are consistent with studies done in health facilities in south Ethiopia and Nairobi County that revealed that most of
the patients interrupted treatment during the intensive phase of treatment [15,16]. Further,
majority of the participants who interrupted treatment had pulmonary TB with a smaller proportion having extra-pulmonary TB. This could be due to the transmission mode of TB being
airborne resulting to the lung parenchyma being most affected by the disease [17]. In addition,
majority of the patients were bacteriologically confirmed cases at the time of treatment
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Fig 3. Kaplan-Meir curves for the treatment phase.
https://doi.org/10.1371/journal.pone.0248820.g003

Table 3. Cox regression estimates of the risk factors for the time to TB drug interruption in patients attending Kiambu County public hospitals (N = 292).
Unadjusted model�

Characteristics
cHR

Std. Err

Adjusted model��

p-value

95%CI

aHR

Std. Err

p-value

95%CI

Sex
Female
Male
Age

ref

ref

0.997

0.128

0.981

0.775–1.283

1.052

0.156

0.714

0.802–1.381

0.998

0.005

0.683

0.989–1.007

0.999

0.005

0.772

0.989–1.008

0.698

0.305–2.216

1.028

0.535

0.958

0.370–2.852

Type of TB
PTB

ref

EPTB

0.822

ref

BMI
Obese

ref

Normal

1.051

0.149

0.727

0.795–1.388

1.118

0.163

0.446

0.40–1.488

Moderate

1.331

0.356

0.284

0.788–2.248

1.436

0.394

0.187

0.839–2.457

Overweight

0.603

0.199

0.127

0.315–1.154

0.543

0.187

0.077

0.276–1.067

Severe

0.954

0.166

0.787

0.678–1.342

0.976

0.183

0.898

0.677–1.407

0.136

0.822

0.795–1.335

1.133

0.159

0.374

0.860–1.493

0.202

< 0.0001

1.232–2.031

HIV status
Negative

ref

Positive

1.03

ref

Phase
Continuation

ref

Intensive

1.504

ref
0.186

0.001

1.181–1.916

1.581

https://doi.org/10.1371/journal.pone.0248820.t003
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interruption. This confers a great risk of continuous community TB transmission prior to conversion to smear negative [18].
Expectedly, majority of our study participants were HIV negative (70.9%). This reflects the
TB prevalence survey that was conducted in Kenya in 2015–2016 which revealed that upto
85% of the population with TB in the country were HIV negative [5]. Despite being returned
back to care and treatment, (33.1%) of the study participants had unfavorable outcomes with
upto (20.9%) interrupting treatment yet again. This informs the need to come up with measures addressing the reasons cited for interruption in order to mitigate this pattern.
Our study revealed that 71.8% of the patients that interrupted treatment cited lack of
knowledge for the missed clinic appointments. Inadequate information on the disease, duration of treatment, as well as risks associated with treatment interruption could contribute to
non-adherence. This echoes previous studies that linked low level of knowledge to treatment
interruption [19,20]. It is thus paramount to uphold patient health education as one of the key
components in TB management. Increase in the level of knowledge on TB will consequently
improve patients’ health seeking behavior. In our study, patient relocation and travelling followed closely as reasons for interrupting treatment. Improving provider to patient relationship, as well as strengthening linkage mechanisms will ensure the patients have access
treatment despite movement from the primary health facility.
Subsequent to TB treatment initiation, majority of the patients feel much better and get
relief from the symptoms of TB. This is due to the bactericidal activity of the TB drugs which
rapidly reduces the bacillary load in a patient [21]. However, this could also attribute to
patients interrupting treatment. Previously studies conducted have associated feeling better as
a contributor to treatment interruption [15,22,23]. Health education on importance of adherence, coupled with close patient follow-up could assist in ensuring patients are retained in care
until treatment completion.
Treatment interruption was highest among males. Social behavior, highly mobile in nature,
as well as poor health seeking behaviors could be a recipe that could contribute to non-adherence. Besides the prevalence survey in Kenya that showed males had a higher risk of acquiring
TB, studies done have shown female gender to be more adherent to treatment unlike their
counterparts [24]. Further, the age group most affected was 25–34 years. This is an age bracket
that is economically productive hence likely to interrupt treatment as they work to sustain
their livelihood.
Treatment interruption remains a major hurdle in the fight against TB. As the study has
revealed, majority of the patients interrupt treatment during the intensive phase. It is apparent
that some of the major reasons of treatment interruption are lack of knowledge, travel, relocation as well as feeling better. Therefore, health education and counseling on TB transmission,
treatment duration, and importance to complete treatment and potential drug adverse effects
could help in strengthening adherence to treatment. Improved health provider to patient relationship, having a reminder sms platform coupled with diarized patients appointments are
ways that could help in reminding the patient of the clinic visits. Patient care centered
approach will also help understand the preferred health facility the patient would want to seek
care. This approach will also help in linkage for the patient in case of need to travel or relocation from the primary health facility.

Strengths
The study setting is unique in that it encompasses both rural and urban settings thus allows for
the analysis of the similarities and various differences of the factors influencing(hindering successful TB treatment among our patients) interruption depending on the patient locality. In
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addition, our study incorporated LFTUs that were returned back to treatment within the TB
treatment period (pre-TB treatment). This ensured that we were able to follow up the patients
to ascertain their treatment outcomes. The period between the treatment interruption and
tracing was within the pre-treatment period hence this reduced recall bias. Our study was able
to incorporate participants from both public and private health facilities making it representative of the health facilities from whole county. The STROBE guidelines for cohort studies
informed the design and reporting for this study. Finally, our study used a standardized MOH
tool to capture details of treatment interruption that was filled by the CHV and verified by
health worker to ensure completeness of documentation in the tracing form.

Study limitation
Some of the study limitations found includes exclusion of some TB treatment interrupters that
were not found during the defaulter tracing exercise as some facilities were not linked with
CHVs, this had the potential to affect the number of patients included in the study as they
were left out of the study. Some of the socioeconomic parameters that could affect patient
treatment outcomes were not recorded (e.g. smoking status, alcohol consumption). The data
collection method was retrospective and relied on the accuracy of data recorded, thus there is
possibility that data were not recorded correctly were excluded in the study. Finally, majority
of treatment interrupters in our study were men, this might have introduced a selection bias in
the population included in our study.

Conclusions
The study showed that treatment interruption is common among males, dominant in the population aged 25–34 years, and among those who stays in Kiambaa and Githunguri sub-counties. The treatment success rate was estimated to be 66.8% while lack of knowledge and
relocation were the major reasons for the treatment interruptions. Patients on intensive phase
of the treatment had higher risk of treatment interruption. To reduce the treatment interruption TB treatment program consider having interventions that target men to educate men on
the dangers of treatment interruptions and middle aged group of the population in order to
ensure treatment completion is embraced.

Supporting information
S1 File. Treatment interruption tracing form.
(DOCX)
S1 Data.
(XLSX)
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